Finally, a sustained release T3 going into Phase I trials

[Kalicocat]

scottpalmermd.com/synthonic...

[jrbarnes]

Would be nice if they could hurry it up 😛

[TSH110 in reply to jrbarnes]

Or even let us have it! Or allow us natures’s T3 in the form of NDT.

[Lotika]

Thank you for sharing some good news!

[dizzy864]

Very interesting. Why do Americans recognise need for T3 when here medical personnel are so against it.We can only hope it becomes available here!

[shaws Administrator in reply to dizzy864]

I think the professionals who've withdrawn two of the most helpful thyroid hormone replacements (NDT - used since 1892 as well as T3) must themselves have an untreated/undiagnosed thyroid condition as their brains are not working at all. Their decisions do not make sense.

[ilenuca in reply to dizzy864]

The Principal Investigator is a Romanian Dr. -Alexandra Dumitrescu

[diogenes Remembering]

The only trouble is that, if it works, it will be patented and that means expense.

[Kalicocat in reply to diogenes]

Yes, that is too bad, however I think there are 3 different companies working on a sustained release formula, I'll go see if I can find the other two. Although this is the one that sounded the most promising to me. If it is successful, then I'm wondering if Pfizer will look into creating one as well with a different sustained release formula as their sales of Cytomel will likely go down after this one hits the market.

[jrbarnes in reply to Kalicocat]

Makes me wonder if I can buy a lab scale, crush up the tablets and put them into slow release capsules myself. Searches online state that liothyronine can be crushed.

[helvella Administrator Thyroid UK in reply to jrbarnes]

You could do that.

But it wouldn't be at all the same as the product being trialled. And, without proof, I certainly wouldn't assume anything like an even rate of release, nor complete release of the dose.

The trial is about poly-zinc-liothyronine (PZL). There might be more recent papers but this is from a couple of years ago:

Da Conceição, Rodrigo R et al. “Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats.” Thyroid : official journal of the American Thyroid Association vol. 28,11 (2018): 1425-1433. doi:10.1089/thy.2018.0205

ncbi.nlm.nih.gov/pmc/articl...

[jrbarnes in reply to helvella]

I read about PZL last year and it looks hopeful.

[Kalicocat in reply to jrbarnes]

I don't think I would try that. Helvella is right, you never know what will actually happen to the absorption of the T3. Plus I think the capsules would have to be quite large and mixed very very well which is pretty difficult without the proper equipment.

[jrbarnes in reply to Kalicocat]

I'd have to be desperate to take it into my own hands so let's hope they get this show on the road with the SRT3. Does your compounding pharmacy use the same method as PZL? My FNP would be open to a SRT3 so I may mention it at my next visit. It would save me from having to quarter my 5mcg pills and stagger them to create the effect of slow release.

[helvella Administrator Thyroid UK in reply to jrbarnes]

PZL is, effectively, a new compound and would not be permitted to be dispensed.

Compounding pharmacies use a variety of substances to try to achieve their effect. But I don't think any have been tested fully and adequately.

This article is quite interesting.

Review ARTICLE

Front. Endocrinol., 13 August 2019 | doi.org/10.3389/fendo.2019....

Sustained Release T3 Therapy: Animal Models and Translational Applications

Thaer Idrees1,

John D. Price2,

Thomas Piccariello2,3 and

Antonio C. Bianco1*

• 1Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Chicago, IL, United States

• 2Synthonics Inc., Blacksburg, VA, United States

• 3Department of Chemistry, Virginia Tech, Blacksburg, VA, United States

The standard of care to treat hypothyroidism is daily administration of levo-thyroxine (LT4). This is based on the understanding that deiodinases can restore production of T3 and compensate for the small amounts of T3 that are normally produced by the thyroid gland. However, pre-clinical and clinical evidence indicating that deiodinases fall short of restoring T3 production is accumulating, opening the possibility that liothyronine (LT3) might have a role in the treatment of some hypothyroid patients. LT3 tablets taken orally result in a substantial peak of circulating T3 that is dissipated during the next several hours, which is markedly distinct from the relative stability of T3 levels in normal individuals. Thus, the effort to developing new delivery strategies for LT3, including slow release tablets, liquid formulations, use of T3-related/hybrid molecules such as T3 sulfate, poly-zinc-T3 and glucagon-T3, nanoparticles containing T3, subcutaneous implant of T3-containing matrices, and stem cells for de novo development of the thyroid gland. This article reviews these strategies, their applicability in animal models and translatability to humans.

frontiersin.org/articles/10...

[Kalicocat in reply to jrbarnes]

No, they use some sort of plant fiber I believe, I can't remember what it is called. It is not very stable, so I get 2 month prescriptions max and have to keep it in the fridge. Stability is what has been the problem with any slow release compound of T3 to this point.

[jrbarnes]

This was a very interesting read. It's exciting to think some of these technologies could be a reality one day. Thanks for sharing.